SCHEMBL6438147

SCHEMBL6438147

CC(N)(C(=O)O)C(F)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 1/20 0.44
CYP1A2 P05177 2/20 0.43
CYP2D6 P10635 2/20 0.43
SRC P12931 1/20 0.39
ATM Q13315 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.39
MAPT P10636 1/20 0.38
KMT2A Q03164 1/20 0.38
HTT P42858 1/20 0.38
RIPK1 Q13546 1/20 0.38
ALOX5 P09917 1/20 0.38
AOC3 Q16853 1/20 0.38
EPHX1 P07099 1/20 0.38
SLC6A4 P31645 1/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22074702 0.85 BLM (0.46) CYP2C19SRCLMNA
SCHEMBL25596204 0.85 ALDH1A1 (0.42) CYP2C19ATMLMNAKMT2AHTT
SCHEMBL6533418 0.81 CYP2C19 (0.44) CYP2C19CYP1A2CYP2D6SRCATM
SCHEMBL6533964 0.79 GAA (0.43) CYP2C19CYP1A2CYP2D6KMT2A
SCHEMBL23723006 0.78 CYP2D6 (0.40) CYP2C19CYP1A2CYP2D6SRCLMNA
SCHEMBL5940495 0.78 CYP2D6 (0.48) CYP2C19CYP1A2CYP2D6SRCATM
SCHEMBL3109358 0.78 AOC3 (0.52) CYP2C19CYP1A2CYP2D6SRCL3MBTL1
SCHEMBL8496310 0.78 CYP2D6 (0.48) CYP2C19CYP1A2CYP2D6SRCATM
SCHEMBL3109355 0.78 AOC3 (0.52) CYP2C19CYP1A2CYP2D6SRCL3MBTL1
SCHEMBL21243976 0.78 SLC6A4 (0.41) LMNARIPK1AOC3SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2005030735-A1 TRIAZINES DERIVATIVES AS CELL ADHESION INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2005-04-07 WO claimed
US-20150045328-A1 DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS ALLERGAN, INC. 2015-02-12 US disclosed
US-20050256160-A1 Beta-alanine derivatives and the use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150045328-A1 DISUBSTITUTED ARYL OXY DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS S1PR1, S1PR3, S1PR2 CYP2C19 2679/4885CYP1A2 1998/4885CYP2D6 1447/4885
US-20050256160-A1 Beta-alanine derivatives and the use thereof TGFB1, PML, APOB CYP2C19 3960/4885CYP1A2 2649/4885CYP2D6 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.